Clinical Trials Logo

Disorder of Skin Donor Site clinical trials

View clinical trials related to Disorder of Skin Donor Site.

Filter by:
  • None
  • Page 1

NCT ID: NCT04299126 Not yet recruiting - Clinical trials for Disorder of Skin Donor Site

Efficacy and Safety of High Absorption Pad in Split-thickness Skin Graft Donor Site Wound

Start date: March 5, 2020
Phase: N/A
Study type: Interventional

High absorption pad for blood and pus with natural antimicrobial agent or gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras) will be randomly covered on half of split-thickness skin graft donor site wound. The another will be cover on another half of split-thickness skin graft donor site wound. Then, they will be covered with gauzes and bandage. Time to wound healing, amounts of covered dressing gauzes, signs of infection, pain score, erythema index, melanin index, trans epidermal water loss index, and adverse events will be evaluated.

NCT ID: NCT02643680 Recruiting - Wound Clinical Trials

Clinical Study of Biocellulose Wound Dressing Containing Silk Sericin and PHMB for STSG Donor Sites

Start date: November 2015
Phase: Phase 2
Study type: Interventional

1. The wound healing time of STSG donor sites which are treated with the novel biocellulose wound dressing containing silk sericin and PHMB should be less or equal to Bactigras®. 2. The wound quality of STSG donor sites which are treated with the novel biocellulose wound dressing containing silk sericin and PHMB should be less or equal to Bactigras®. 3. The amounts of STSG donor site infection which are treated with the novel biocellulose wound dressing containing silk sericin and PHMB should not be more than Bactigras®. 4. The pain level of STSG donor sites which are treated with the novel biocellulose wound dressing containing silk sericin and PHMB should be less or equal to Bactigras®. 5. Adverse events which are occurred from the novel biocellulose wound dressing containing silk sericin and PHMB treatment for STSG donor sites and Bactigras® will be reported, if they occur.

NCT ID: NCT02400372 Recruiting - Clinical trials for Disorder of Skin Donor Site

The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site

Start date: May 2015
Phase: Phase 4
Study type: Interventional

The study, "Evaluation of the effect of antibacterial medical honey dressing for healing of implants donor area", is a Phase 4 Study, Prospective, A randomized trial, 3 arms (treatment groups) trial, Open-label, non-controlled, non-randomized, Aims To test the effectiveness of antibacterial medical honey dressing in the therapy of donor area of implants. In our Research Will participate in 135 new patients over the age of 18, with a wound in the donor area of hip implants, Hospitalized in the Plastic Surgery Unit of the "Haemek" Medical Center. Appropriate patients, who will agree to sign and sign a consent form, be assigned randomly to one of three treatment groups: 1. The research group: Medihoney antibacterial wound dressing. 2. The control group: Paraffin gauze with saline- The basic treatment in the donor site, accepted the literature. 3. Comparison group: Polymem dressing - Common treatment in the donor site in the Plastic Surgery Unit of the "Haemek" Medical Center. Participants in the three study groups will be performed, each visit, Medical monitoring and examination by a team of medical indices of Plastic Surgery Unit, as is customary. The treatment will be performed, twice a week until recovery and the complete closure of the wound.

NCT ID: NCT01974583 Completed - Clinical trials for Wound Healing Disturbance of

Wound-healing Improvement by Resurfacing Split-Thickness Skin Donor Sites With Thin Split-thickness Grafting

Start date: January 2002
Phase: N/A
Study type: Observational [Patient Registry]

Split-thickness skin grafting remains fundamental treatment of patients with deep burns and other traumatic injuries. However, the split-thickness skin graft (STSG) donor site dressing has been controversial until now. Our study here aimed to assess patient comfort and wound-healing efficacy with the application of thin split-thickness grafting on STSG donor sites.